公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort | Chow L.Q.M.; Haddad R.; Gupta S.; Mahipal A.; Mehra R.; Tahara M.; Berger R.; Eder J.P.; Burtness B.; Lee S.-H.; Keam B.; Kang H.; Muro K.; Weiss J.; Geva R.; CHIA-CHI LIN ; Chung H.C.; Meister A.; Dolled-Filhart M.; Pathiraja K.; Cheng J.D.; Seiwert T.Y. | Journal of Clinical Oncology | 663 | 141 | |
2018 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012 | Mehra R.; Seiwert T.Y.; Gupta S.; Weiss J.; Gluck I.; Eder J.P.; Burtness B.; Tahara M.; Keam B.; Kang H.; Muro K.; Geva R.; Chung H.C.; CHIA-CHI LIN ; Aurora-Garg D.; Ray A.; Pathiraja K.; Cheng J.; Chow L.Q.M.; Haddad R. | British Journal of Cancer | 303 | 256 |